keyword
MENU ▼
Read by QxMD icon Read
search

"immune checkpoint inhibitor"

keyword
https://www.readbyqxmd.com/read/29684573/bevacizumab-reduces-s100a9-mdsc-linked-to-intracranial-control-in-patients-with-egfr-mutant-lung-adenocarcinoma
#1
Po-Hao Feng, Kuan-Yuan Chen, Yu-Chen Huang, Ching-Shan Luo, Shen Ming Wu, Tzu-Tao Chen, Chun-Nin Lee, Chi-Tai Yeh, Hsiao-Chi Chuang, Chia-Li Han, Chiou-Feng Lin, Wei-Hwa Lee, Chih-Hsi Kuo, Kang-Yun Lee
BACKGROUND: In vitro models have demonstrated immune-modulating effects of bevacizumab. Combinations of EGFR tyrosine kinase inhibitor (TKI) with bevacizumab improve progression free survival (PFS) in patients with EGFR mutated lung adenocarcinoma. How bevacizumab confers this clinical effect and underlying mechanisms are not clear. PATIENT AND METHODS: Fifty-five patients with stage 4 EGFR mutated lung adenocarcinoma were enrolled. Myeloid derived suppressor cells (MDSCs), T helper cells (Th1/Th2) and cytotoxic T lymphocytes (CTLs) were analyzed by flow cytometry...
April 20, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29684232/immune-checkpoint-inhibitor-therapy-in-patients-with-autoimmune-disease
#2
Douglas B Johnson, Kathryn E Beckermann, Daniel Y Wang
Immune checkpoint inhibitors have demonstrated efficacy across many cancer types in numerous clinical trials. However, because patients with preexisting autoimmune disease were excluded from these seminal trials, there are serious gaps in knowledge regarding the efficacy-and in particular the safety-of these transformative agents in patients with autoimmune disease. The safety of immune checkpoint inhibitors in this population has been an important concern, since these agents unleash immune activation, a potentially dangerous situation for patients with already heightened and aberrant immune function...
April 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29684049/clinical-factors-associated-with-early-progression-and-grade-3-4-toxicity-in-patients-with-advanced-non-small-cell-lung-cancers-treated-with-nivolumab
#3
Coraline Dumenil, Marie-Ange Massiani, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Thierry Chinet, Etienne Giroux Leprieur
INTRODUCTION: The prognosis of advanced non-small-cell lung cancer (NSCLC) has been improved by development of immune checkpoint inhibitors (ICIs) such as nivolumab for second-line treatment. As phase III trials include only selected patients, we here investigated the clinical factors associated with efficacy and safety of nivolumab in 'real life' patients with advanced NSCLC. METHODS: Clinical and histological characteristics, therapies and survival data of all consecutive patients with advanced NSCLC included prospectively and treated by nivolumab in two French academic hospitals between February 2015 and December 2016 were examined...
2018: PloS One
https://www.readbyqxmd.com/read/29681813/hyperprogressive-disease-in-the-irradiation-field-after-a-single-dose-of-nivolumab-for-gastric-cancer-a-case-report
#4
Takatsugu Ogata, Hironaga Satake, Misato Ogata, Yukimasa Hatachi, Hisateru Yasui
Following the ATTRACTION-2 study, nivolumab was approved for advanced gastric cancer in Japan. However, pseudoprogression and hyperprogressive disease have been reported in patients treated with immune checkpoint inhibitors. We report a patient with gastric cancer who received nivolumab after radiotherapy only to experience rapid progression within the irradiation field after the first immunotherapy session. A 66-year-old man with dysphagia visited our hospital and was diagnosed with stage IV gastroesophageal cancer (human epidermal growth factor receptor-2 score = 0)...
January 2018: Case Reports in Oncology
https://www.readbyqxmd.com/read/29681426/tumor-inherent-interferons-impact-on-immune-reactivity-and-immunotherapy
#5
Natasha K Brockwell, Belinda S Parker
Immunotherapy has revolutionized cancer treatment, with sustained responses to immune checkpoint inhibitors reported in a number of malignancies. Such therapeutics are now being trialed in aggressive or advanced cancers that are heavily reliant on untargeted therapies, such as triple negative breast cancer. However, responses have been underwhelming to date and are very difficult to predict, leading to an inability to accurately weigh up the benefit-to-risk ratio for their implementation. The tumor immune microenvironment has been closely linked to immunotherapeutic response, with superior responses observed in patients with T cell-inflamed or 'hot' tumors...
April 19, 2018: Cytokine
https://www.readbyqxmd.com/read/29680016/immune-checkpoint-inhibitors-and-the-union-of-bugs-against-cancer
#6
Gregg J Silverman, Doua F Azzouz, Adam Mor
No abstract text is available yet for this article.
May 2018: Kidney International
https://www.readbyqxmd.com/read/29678394/-dermatologic-toxicities-of-immune-checkpoint-inhibitors
#7
REVIEW
V Sibaud, S Boulinguez, C Pagès, L Riffaud, L Lamant, C Chira, S Boyrie, E Vigarios, E Tournier, N Meyer
The development of immune checkpoint inhibitors (monoclonal antibodies targeting PD-1/PD-L1 or CTLA-4) represents a significant advance in the treatment of multiple cancers. Given their particular mechanism of action, which involves triggering CD4+/CD8+ T-cell activation and proliferation, they are associated with a specific safety profile. Their adverse events are primarily immune-related, and can affect practically all organs. In this context, dermatological toxicity is the most common, though it mostly remains mild to moderate and does not require discontinuation of treatment...
April 17, 2018: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/29678298/targeting-wnt-%C3%AE-catenin-signaling-for-cancer-immunotherapy
#8
REVIEW
Bojun Wang, Tian Tian, Karl-Henning Kalland, Xisong Ke, Yi Qu
Despite the dramatic antitumor efficiency of certain immune checkpoint inhibitors, immunotherapy has met a bottleneck regarding the response rate and resistance in cancer patients. Increasing evidence indicates that Wnt/β-catenin signaling, one of the best-characterized cancer drivers, promotes cancer progression by regulating the tumor-immune cycle in most of the nodes, including dendritic cells, T cells, and tumor cells. Specifically, abnormal Wnt/β-catenin signaling directly alters a number of regulators critical for the antitumor activities of T cells, especially effector T cells, T helper cells, and regulatory T cells...
April 17, 2018: Trends in Pharmacological Sciences
https://www.readbyqxmd.com/read/29678194/the-perfect-personalized-cancer-therapy-cancer-vaccines-against-neoantigens
#9
REVIEW
Luigi Aurisicchio, Matteo Pallocca, Gennaro Ciliberto, Fabio Palombo
In the advent of Immune Checkpoint inhibitors (ICI) and of CAR-T adoptive T-cells, the new frontier in Oncology is Cancer Immunotherapy because of its ability to provide long term clinical benefit in metastatic disease in several solid and liquid tumor types. It is now clear that ICI acts by unmasking preexisting immune responses as well as by inducing de novo responses against tumor neoantigens. Thanks to theprogress made in genomics technologies and the evolution of bioinformatics, neoantigens represent ideal targets, due to their specific expression in cancer tissue and the potential lack of side effects...
April 20, 2018: Journal of Experimental & Clinical Cancer Research: CR
https://www.readbyqxmd.com/read/29677240/uveal-effusion-after-immune-checkpoint-inhibitor-therapy
#10
Merina Thomas, Stephen T Armenti, M Bernadete Ayres, Hakan Demirci
Importance: Immune checkpoint inhibitors, including antiprogrammed cell death protein-1 (anti-PD-1) and antiprogrammed cell death ligand-1 (anti-PD-L1) monoclonal antibodies, have recently been introduced as a promising new immunotherapy for solid cancers. The adverse effects typically include inflammation of the skin, endocrine, and gastrointestinal systems. Objective: To describe 3 patients who developed uveal effusion after initiating anti-PD-1 and anti-PD-L1 monoclonal antibody therapy...
April 12, 2018: JAMA Ophthalmology
https://www.readbyqxmd.com/read/29675791/chemotherapy-treatment-is-associated-with-altered-pd-l1-expression-in-lung-cancer-patients
#11
Lívia Rojkó, Lilla Reiniger, Vanda Téglási, Katalin Fábián, Orsolya Pipek, Attila Vágvölgyi, László Agócs, János Fillinger, Zita Kajdácsi, József Tímár, Balázs Döme, Zoltán Szállási, Judit Moldvay
OBJECTIVES: While the predictive value of programmed cell death ligand-1 (PD-L1) protein expression for immune checkpoint inhibitor therapy of lung cancer has been extensively studied, the impact of standard platinum-based chemotherapy on PD-L1 or programmed cell death-1 (PD-1) expression is unknown. The aim of this study was to determine the changes in PD-L1 expression of tumor cells (TC) and immune cells (IC), in PD-1 expression of IC, and in the amount of stromal mononuclear cell infiltration after platinum-based chemotherapy in patients with lung cancer...
April 19, 2018: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29675018/contribution-to-tumor-angiogenesis-from-innate-immune-cells-within-the-tumor-microenvironment-implications-for-immunotherapy
#12
REVIEW
Adriana Albini, Antonino Bruno, Douglas M Noonan, Lorenzo Mortara
The critical role of angiogenesis in promoting tumor growth and metastasis is strongly established. However, tumors show considerable variation in angiogenic characteristics and in their sensitivity to antiangiogenic therapy. Tumor angiogenesis involves not only cancer cells but also various tumor-associated leukocytes (TALs) and stromal cells. TALs produce chemokines, cytokines, proteases, structural proteins, and microvescicles. Vascular endothelial growth factor (VEGF) and inflammatory chemokines are not only major proangiogenic factors but are also immune modulators, which increase angiogenesis and lead to immune suppression...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29672367/characterization-of-pd-l1-and-pd-1-expression-and-cd8-tumor-infiltrating-lymphocyte-in-epstein-barr-virus-associated-nasopharyngeal-carcinoma
#13
Noppadol Larbcharoensub, Komkrit Mahaprom, Chuleeporn Jiarpinitnun, Narumol Trachu, Nattha Tubthong, Poompis Pattaranutaporn, Ekaphop Sirachainan, Nuttapong Ngamphaiboon
OBJECTIVES: Immunotherapies that target the programmed death-1/ programmed death-1 ligand (PD-1/PD-L1) immune checkpoint pathway have shown promise in nasopharyngeal carcinoma (NPC) in early phases clinical studies. Here, we evaluated PD-1 and PD-L1 expression and CD8+ tumor-infiltrating lymphocytes (TILs) in NPC patients. MATERIALS AND METHODS: Newly diagnosed NPC patients were identified through the institutional database between January 2007 and December 2012...
April 18, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29670880/targeting-tumor-associated-macrophages-as-a-potential-strategy-to-enhance-the-response-to-immune-checkpoint-inhibitors
#14
REVIEW
Luca Cassetta, Takanori Kitamura
Inhibition of immune checkpoint pathways in CD8+ T cell is a promising therapeutic strategy for the treatment of solid tumors that has shown significant anti-tumor effects and is now approved by the FDA to treat patients with melanoma and lung cancer. However the response to this therapy is limited to a certain fraction of patients and tumor types, for reasons still unknown. To ensure success of this treatment, CD8+ T cells, the main target of the checkpoint inhibitors, should exert full cytotoxicity against tumor cells...
2018: Frontiers in Cell and Developmental Biology
https://www.readbyqxmd.com/read/29669928/cx3cr1-identifies-pd-1-therapy-responsive-cd8-t-cells-that-withstand-chemotherapy-during-cancer-chemoimmunotherapy
#15
Yiyi Yan, Siyu Cao, Xin Liu, Susan M Harrington, Wendy E Bindeman, Alex A Adjei, Jin Sung Jang, Jin Jen, Ying Li, Pritha Chanana, Aaron S Mansfield, Sean S Park, Svetomir N Markovic, Roxana S Dronca, Haidong Dong
Although immune checkpoint inhibitors have resulted in durable clinical benefits in a subset of patients with advanced cancer, some patients who did not respond to initial anti-PD-1 therapy have been found to benefit from the addition of salvage chemotherapy. However, the mechanism responsible for the successful chemoimmunotherapy is not completely understood. Here we show that a subset of circulating CD8+ T cells expressing the chemokine receptor CX3CR1 are able to withstand the toxicity of chemotherapy and are increased in patients with metastatic melanoma who responded to chemoimmunotherapy (paclitaxel and carboplatin plus PD-1 blockade)...
April 19, 2018: JCI Insight
https://www.readbyqxmd.com/read/29669262/dna-mismatch-repair-in-cancer
#16
REVIEW
Marina Baretti, Dung T Le
Microsatellite instability (MSI) refers to the hypermutator phenotype secondary to frequent polymorphism in short repetitive DNA sequences and single nucleotide substitution, as consequence of DNA mismatch repair (MMR) deficiency. MSI secondary to germline mutation in DNA MMR proteins is the molecular fingerprint of Lynch syndrome (LS), while epigenetic inactivation of these genes is more commonly found in sporadic MSI tumors. MSI occurs at different frequencies across malignancies, although original methods to assess MSI or MMR deficiency have been developed mostly in LS related cancers...
April 15, 2018: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29667757/successful-treatment-with-nivolumab-for-lung-cancer-with-low-expression-of-pd-l1-and-prominent-tumor-infiltrating-b-cells-and-immunoglobulin-g
#17
Takayuki Suyama, Yuichi Fukuda, Hiroshi Soda, Daiki Ogawara, Keisuke Iwasaki, Takuya Hara, Masataka Yoshida, Tatsuhiko Harada, Asuka Umemura, Hiroyuki Yamaguchi, Hiroshi Mukae
Little is known about the anti-tumor activity of humoral immunity in lung cancer patients treated with nivolumab, an immune checkpoint inhibitor. Herein, we report a case of lung cancer with 5% expression of PD-L1, in which a partial response to nivolumab was sustained for > 7 months. Immunohistochemical analysis of the metastatic lymph node biopsy specimen showed prominent accumulation of plasma cells and immunoglobulin G. These findings suggest that pre-existing humoral immunity may be worth considering as a candidate therapeutic biomarker of nivolumab in some lung cancer patients...
April 18, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29667169/expression-of-scavenger-receptor-marco-defines-a-targetable-tumor-associated-macrophage-subset-in-non-small-cell-lung-cancer
#18
Linnéa La Fleur, Vanessa F Boura, Andrey Alexeyenko, Anders Berglund, Victor Pontén, Johanna Sm Mattsson, Dijana Djureinovic, Johan Persson, Hans Brunnström, Johan Isaksson, Eva Brandén, Hirsh Koyi, Patrick Micke, Mikael Ci Karlsson, Johan Botling
Tumor-associated macrophages (TAMs) are attractive targets for immunotherapy. Recently, studies in animal models showed that treatment with an anti-TAM antibody directed against the scavenger receptor MARCO resulted in suppression of tumor growth and metastatic dissemination. Here we investigated the expression of MARCO in relation to other macrophage markers and immune pathways in a non-small cell lung cancer (NSCLC) cohort (n=352). MARCO, CD68, CD163, MSR1 and programmed death ligand-1 (PD-L1) were analyzed by immunohistochemistry and immunofluorescence, and associations to other immune cells and regulatory pathways were studied in a subset of cases (n=199) with available RNA-seq data...
April 18, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29666811/immune-checkpoint-pathways-in-non-small-cell-lung-cancer
#19
REVIEW
Young Kwang Chae, Ayush Arya, Wade Iams, Marcello Cruz, Nisha Mohindra, Victoria Villaflor, Francis J Giles
Immunotherapy has evolved at a phenomenal pace in cancer therapeutics. This has primarily been fueled by the much perceived necessity to procure an alternative to current standard of care chemotherapy agents, owing to several concerns such as treatment-related toxicity and poor long-term survival associated with the same. The knowledge of various mechanisms involved in regulation of immune response to cancer cells has served a fundamental role in identifying key molecules through which immune cell activity may be modulated...
March 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29666801/current-therapeutic-landscape-for-advanced-gastroesophageal-cancers
#20
REVIEW
Anthony Lopez, Kazuto Harada, Dilsa Mizrak Kaya, Jaffer A Ajani
Treatment of advanced gastroesophageal cancers remains challenging for clinicians, patients, and caregivers alike. Despite considerable research, the therapeutic armamentarium is restricted and hardly personalized. In the first-line setting, trastuzumab with a fluoropyrimidine and platinum agent is the standard-of-care in patients with HER2-positive tumor. For the others, a platinum-based doublet (preferably with oxaliplatin) is recommended. Three-drug cytotoxic regimens should be reserved for exceptional cases where patients have good performance status...
February 2018: Annals of Translational Medicine
keyword
keyword
100072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"